{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(1)"],"submitter":["Garcia-Romeu A"],"pubmed_abstract":["Lyme disease, caused by the bacterium Borrelia burgdorferi, is the most common vector-borne disease in the United States and Europe. Although antibiotics effectively treat most cases, an estimated 10-20% of patients develop post-treatment Lyme disease (PTLD), a chronic syndrome marked by fatigue, pain, cognitive difficulties, mood disturbance, and reduced quality of life. There are no established treatments for PTLD. The serotonin 2A receptor agonist psychedelic psilocybin has recently shown potential antidepressant and anxiolytic effects in clinical trials as well as preliminary evidence for anti-inflammatory effects in animals. This open-label, single-arm pilot study evaluated the effects of psilocybin in 20 participants with well-characterized PTLD. The 8-week intervention included two "],"journal":["Scientific reports"],"pagination":["7497"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12936178"],"repository":["biostudies-literature"],"pubmed_title":["Pilot study of psilocybin in patients with post-treatment lyme disease."],"pmcid":["PMC12936178"],"pubmed_authors":["Aucott JN","Yaffe A","Soloski MJ","Rebman AW","Garcia-Romeu A","Geithner I","Naude GP","So S","Kozero EA","Yang T"],"additional_accession":[]},"is_claimable":false,"name":"Pilot study of psilocybin in patients with post-treatment lyme disease.","description":"Lyme disease, caused by the bacterium Borrelia burgdorferi, is the most common vector-borne disease in the United States and Europe. Although antibiotics effectively treat most cases, an estimated 10-20% of patients develop post-treatment Lyme disease (PTLD), a chronic syndrome marked by fatigue, pain, cognitive difficulties, mood disturbance, and reduced quality of life. There are no established treatments for PTLD. The serotonin 2A receptor agonist psychedelic psilocybin has recently shown potential antidepressant and anxiolytic effects in clinical trials as well as preliminary evidence for anti-inflammatory effects in animals. This open-label, single-arm pilot study evaluated the effects of psilocybin in 20 participants with well-characterized PTLD. The 8-week intervention included two ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T21:56:57.04Z","creation":"2026-07-10T03:15:59.423Z"},"accession":"S-EPMC12936178","cross_references":{"pubmed":["41741501"],"doi":["10.1038/s41598-026-38091-9"]}}